Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05134779 · ClinicalTrials.gov registry record
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
A clinical trial of Breast Cancer, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- 400
- Enrollment target
- 2
- Study locations
NCT05134779: Recruiting study of Breast Cancer, sponsored by Weill Medical College of Cornell University.
NCT05134779 is a study of Breast Cancer that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05134779, a study of Breast Cancer, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
Primary Outcome
Tumor tissue will be obtained at key inflection points from breast cancer patients (BC): at initial diagnosis, at surgery and at metastasis or recurrence. Patient Derived Organoids (PDOs) will be prepared from tumors that are obtained from the BC patients.
Conditions Studied
Interventions
- PROCEDURE Live Biobank
Study Locations (2)
New York
- Brooklyn Methodist Hospital - NewYork Presbyterian - New York
- New York Presbyterian Hospital - Queens - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2028-12-31 |
What NCT05134779 shows while recruiting
NCT05134779 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Live Biobank is the first listed.
NCT05134779 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05134779 about?
NCT05134779 is a clinical study titled "De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You". This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
What is the current status of trial NCT05134779?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2022-01-12. Estimated completion is 2028-12-31.
What conditions does trial NCT05134779 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05134779?
The interventions under investigation include: Live Biobank (PROCEDURE).
Who is sponsoring clinical trial NCT05134779?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05134779 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05134779's enrollment target sits among peer trials
400 233rd of 1224 higher than 981 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02285582 · 400 participants
International Rare Histiocytic Disorders Registry (IRHDR)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI